Promosome announces the appointments of Edward R. Robinson and Loren A. Busby to its Board of Managers
New York, NY, November 22, 2011 - New York, NY, November 22, 2011 - Promosome LLC, a privately held biotechnology company specializing in innovative technologies related to the regulation of protein synthesis, has announced the expansion of its Board of Managers. To further augment its corporate structure and support for its technology commercialization efforts, Promosome is pleased to announce the addition of Mr. Edward R. Robinson and Ms. Loren A. Busby.
"We are pleased to welcome Ed and Loren to our Board. Their extensive experience in biotherapeutic business development and finance will be an asset to our Board and beneficial to the company's future growth," said William J. Gedale, Chairman of the Promosome Board of Managers.
Mr. Robinson brings to Promosome nearly 30 years in life sciences experience and a strong background in contract manufacturing for bio-therapeutics and industrial enzymes. During his distinguished career, he has been President of Lonza Biologics, Inc., President of Solutia's Pharmaceutical Services Division, Executive Vice President of Pharma and Biopharmaceuticals for Cambrex Corporation, as well as Vice President of Asia Pacific for Genencor International. In addition, as an independent advisor or non-executive board director, Mr. Robinson has worked with life science and investment companies in the US and Europe in the areas of business development, strategy and corporate development. Mr. Robinson holds a bachelor's degree from Clarkson University and an MBA from the Rochester Institute of Technology. He also attended the Executive Management Program at Pennsylvania State University.
Ms. Busby has over 20 years of experience in the venture capital industry and currently provides financial and advisory services to fund managers and small businesses under the moniker Cresco Advisors LLC. She was previously a Partner at NGN Capital, a $400 million healthcare-focused venture fund, and before that was with Walden Capital Partners, LP where she sourced and managed several small- to mid-size investments in the manufacturing, distribution and technology sectors. Ms. Busby earned a B.S. from Central Connecticut State University and an MBA from Columbia University where she was a McCain Scholar. She is a member of the New York Society of Security Analysts, where she served as Chairman and Vice-Chairman of its Alternative Investments Committee. She is a Chartered Financial Analyst.
Promosome is a New York City based biotechnology company founded to commercialize the discoveries of Nobel Laureate, Dr. Gerald M. Edelman, and Dr. Vincent P. Mauro of The Scripps Research Institute (TSRI) in La Jolla, California. Leveraging Drs. Edelman and Mauro's unparalleled expertise in the areas of mRNA translation, Promosome offers technology licensing opportunities for biotherapeutic and bioindustrial companies to improve expression efficiencies and the time to cell line development. The company has its own developmental facility in La Jolla as well as an ongoing Research Funding and Option Agreement (RFO) with these TSRI based researchers.
Promosome also established a technology license and equity relationship with Recopharma AB of Stockholm, Sweden and is currently advancing additional partnering and evaluation relationships with industry-leading contract manufacturers, biopharmaceutical and industrial bioproduction based companies. To augment its commercial initiatives, the company has recently established a La Jolla based developmental laboratory facility.
For more information on Promosome's technology and Promosome corporate information, please visitwww.promosome.com
SOURCE: Promosome LLC
John F. Manzello, CEO, +1-508-845-2255, or email@example.com